Also trades as: ADAP (NASDAQ) · $vol 5M
ADAPY OTC
Adaptimmune Therapeutics plc
1W: +45.1%
1M: +48.0%
3M: -5.1%
YTD: +5.6%
1Y: -69.5%
3Y: -95.4%
5Y: -99.4%
$0.04
-0.00 (-2.63%)
Weekly Expected Move ±21.4%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$246M
-13.0% ▼
5Y CAGR: +6.3%
Total Liabilities
$234M
-3.7% ▼
5Y CAGR: +32.2%
Shareholders Equity
$12M
-70.0% ▼
5Y CAGR: -37.4%
Cash & Investments
$152M
+3.2% ▲
5Y CAGR: +11.1%
Total Debt
$74M
+194.1% ▲
5Y CAGR: +23.9%
Net Debt
-$17M
+85.7% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $57M | $150M | $108M | $144M | $91M |
| Short-Term Investments | $311M | $220M | $97M | $3M | $60M |
| Cash & ST Investments | $368M | $370M | $205M | $147M | $152M |
| Net Receivables | $21M | $34M | $38M | $47M | $16M |
| Inventory | $0 | $0 | $0 | $0 | $7M |
| Other Current Assets | $3M | $3M | $3M | $4M | $3M |
| Total Current Assets | $398M | $415M | $255M | $208M | $188M |
| Property, Plant & Equip. | $47M | $51M | $72M | $72M | $51M |
| Goodwill & Intangibles | $2M | $1M | $442K | $330K | $4M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Assets | $5M | $2M | $2M | $3M | $3M |
| Total Non-Current Assets | $53M | $54M | $74M | $75M | $58M |
| Total Assets | $451M | $470M | $329M | $283M | $246M |
| — Liabilities — | |||||
| Accounts Payable | $6M | $8M | $5M | $8M | $9M |
| Short-Term Debt | $0 | $2M | $3M | $0 | $5M |
| Deferred Revenue | $3M | $22M | $24M | $29M | $12M |
| Other Current Liabilities | $15M | $12M | $13M | $16M | $17M |
| Total Current Liabilities | $39M | $63M | $65M | $73M | $65M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $50M |
| Other Non-Current Liab. | $644K | $673K | $1M | $1M | $4M |
| Total Non-Current Liabilities | $71M | $201M | $183M | $170M | $170M |
| Total Liabilities | $110M | $264M | $247M | $243M | $234M |
| — Equity — | |||||
| Common Stock | $1M | $1M | $1M | $2M | $2M |
| Retained Earnings | -$586M | -$744M | -$909M | -$1.0B | -$1.1B |
| Accumulated OCI | -$10M | -$11M | -$875K | -$4M | -$2M |
| Total Stockholders Equity | $341M | $206M | $82M | $40M | $12M |
| Total Liabilities & Equity | $451M | $470M | $329M | $283M | $246M |
| — Key Metrics — | |||||
| Total Debt | $24M | $25M | $23M | $25M | $74M |
| Net Debt | -$33M | -$124M | -$85M | -$119M | -$17M |
| Total Investments | $311M | $220M | $97M | $3M | $60M |